U.S. court rejects Alvogen's patent challenge for Celgene's cancer drug

The U.S. patent office on Thursday rejected a filing by Alvogen Pine Brook Llc for a review challenging patents on Celgene Corp's blockbuster myeloma drug Revlimid.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news